Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-23

Study Completion Date

2020-04-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary embolism (PE) is a serious disease with frequent intra hospital mortality remains high. If anticoagulation is perfectly codified, the remainder of the initial management has been less studied.

In particular, the "conditioning" Initial often involves systematic plasma volume of 250 to 500 cc, by analogy to other situations. But this treatment option is not based on factual data. In the right ventricular dysfunction that often accompany severe EP, volume expansion may instead be harmful, according to the law of Frank Starling. A retrospective study has recently shown a benefit of diuretic therapy in patients hospitalized for severe normotensive EP.

The proposed study is interventional, prospective, multicenter, randomized, require to include 60 patients.

The main objective of the study is the comparison of the troponin normalization period Ic (biomarker of right ventricular dysfunction) in patients hospitalized in the initial phase of a serious normotensive EP, between the 2 groups diuretic and filling Vascular.

The primary endpoint is the time in hours standardization of troponin Ic.

The secondary endpoints will be:

* the period of normalization of Brain Natriuretic Peptide (BNP)
* changes in echocardiographic parameters of right ventricular dysfunction
* a composite endpoint: cardiovascular death / cardiogenic shock / use of amines / use of thrombolysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension

NCT05861479

Pulmonary Arterial Hypertension Chronic Thromboembolic Pulmonary Hypertension Acute Right Heart Failure

COMPLETED

Short-term Clinical Deterioration After Acute Pulmonary Embolism

NCT03915925

Pulmonary Embolism

COMPLETED

Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study

NCT02601846

Pulmonary Embolism

COMPLETED

Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism

NCT01326507

Pulmonary Embolism

COMPLETED NA

Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism

NCT01134068

Pulmonary Embolism

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Main objective:

Compared with the time of normalization of cTnI (biomarker of right ventricular dysfunction) in hospitalized patients in the initial phase of a serious EP normotensive between the 2 groups diuretic and vascular filling

PRINCIPAL INCLUSION CRITERIA

* older than 18 Patient
* Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by a chest CT)

The serious nature without hypotension is defined by the presence of:

* From biological criteria: troponin and / or BNP positive AND
* In sonographic criteria: dilated right ventricle defined by echocardiography right over left ventricle ratio (VG)\> 0.9 in apical 4- chamber or 0.7 in large parasternal axis and right ventricular systolic dysfunction (TAPSE \<16 mm and S 'pulsed TDI tricuspid \<10 cm / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial Pressure with systolic (PAPs)\> 35 mmHg or paradoxical septum

* Informed consent signed
* Affiliation to social security

PRINCIPAL EXCLUSION CRITERIA

* Thrombolysis before inclusion
* State of cardiogenic shock defined as systolic BP \<90 mmHg or a drop of\> 40 mmHg in systolic BP for\> 15 minutes
* severe chronic renal impairment defined by clearance \<30 ml / min.
* pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier: cthC5Fc14NkHBXHkFCiTvGcJ8a8= Page 15/26 women of childbearing age and the results will be communicated to the patient by a doctor of his choice)
* Most People under guardianship
* hospitalized without their consent and not protected by law No
* Private person of liberty
* Residence time of more than 24 hours in another department after the positive diagnosis of pulmonary embolism

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Furosémide

Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output \<500 cc / 24 at the 4th hour.

Establishment of an infusion G5 500cc% in "vein custody."

Group Type EXPERIMENTAL

Furosemide

Intervention Type DRUG

furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc

NaCl 9% isotonic

Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an "empirical" in severe EP and this group is therefore the control group.

Group Type ACTIVE_COMPARATOR

NaCl 9% isotonic

Intervention Type DRUG

normal saline 500 cc / 4 hours and 1 L / 24 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Furosemide

furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc

Intervention Type DRUG

NaCl 9% isotonic

normal saline 500 cc / 4 hours and 1 L / 24 hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

diuretic vascular filling fluid replacement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized in the first 24 hours of a serious EP normotensive formally diagnosed (by a chest CT)

The serious nature without hypotension is defined by the presence of:

* From biological criteria: troponin and / or BNP positive AND
* In sonographic criteria: dilated right ventricle defined by echocardiography right over left ventricle ratio (VG)\> 0.9 in apical 4- chamber or 0.7 in large parasternal axis and right ventricular systolic dysfunction (TAPSE \<16 mm and S 'pulsed TDI tricuspid \<10 cm / sec) or pulmonary arterial hypertension (PAH) Pulmonary Arterial Pressure with systolic (PAPs)\> 35 mmHg or paradoxical septum
* Informed consent signed
* Affiliation to social security

Exclusion Criteria

* Thrombolysis before inclusion
* State of cardiogenic shock defined as systolic BP \<90 mmHg or a drop of\> 40 mmHg in systolic BP for\> 15 minutes
* severe chronic renal impairment defined by clearance \<30 ml / min.
* pregnant or nursing woman (a pregnancy test will be performed for XML File Identifier: cthC5Fc14NkHBXHkFCiTvGcJ8a8=
* women of childbearing age and the results will be communicated to the patient by a doctor of his choice)
* Most People under guardianship
* hospitalized without their consent and not protected by law No
* Private person of liberty
* Residence time of more than 24 hours in another

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No